Potential for Molecular Targeted Therapy for Adult T-Cell Leukemia/Lymphoma

REFERENCES

• Yoshida M., Seiki M., Yamaguchi K., Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human Tcell leukemia virus in the disease. Proc. Natl. Acad. Sci. USA, 1984; 81: 2534–2537
   PubMed Web of Science ®Google Scholar
• Shuh M., Beilke M. The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM). Microsc. Res. Tech. 2005; 68(3–4)176–96
   PubMed Web of Science ®Google Scholar
• Matsuoka M., Jeang K. T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 2007; 7(4)270–280
   PubMed Web of Science ®Google Scholar
• Nicot C. Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am. J. Hematol. 2005; 78(3)232–239
   PubMed Web of Science ®Google Scholar
• Taylor G. P., Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005; 24(39)6047–6057
   PubMed Web of Science ®Google Scholar
• Tanaka A., Takahashi C., Yamaoka S., Nosaka V., Maki M., Hatanaka M. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc. Natl. Acad. Sci. USA 1990; 87: 1071–1075
   PubMed Web of Science ®Google Scholar
• Akagi T., Ono H., Shimotohno K. Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1. Blood 1995; 86: 4243–4249
   PubMed Web of Science ®Google Scholar
• Gaudray G., Gachon F., Basbous J., et al. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J. Virol. 2002; 76: 12813–12822
   PubMed Web of Science ®Google Scholar
• Satou Y., Yasunaga J., Yoshida V., Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc. Natl. Acad. Sci. USA 2006; 103: 720–725
   PubMed Web of Science ®Google Scholar
• Arnold J., Yamamoto B., Li M., et al. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 2006; 107: 3976–3982
   PubMed Web of Science ®Google Scholar
• Suzuki T., Hirai H., Fujisawa J., Fujita T., Yoshida M. A transactivator Tax of human T-cell leukemia virus type 1 binds to NF-kB p50 and serum response factor (SRF) and associates with enhancer DNAs of the NF-kB site and CArG box. Oncogene 1993; 8: 2391–2397
   PubMed Web of Science ®Google Scholar
• Tsukahara T., Kannagi M., Ohashi T., Kato H., Arai M., Nunez G., Iwanaga Y., Yamamot N., Ohtani K., Nakamura M., Fujii M. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kB in apoptosis-resistant T-cell transfectants with Tax. J. Virol. 1999; 73: 7981–7987
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., White J. D., Goldman C. K., et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993; 82: 1701–1712
   PubMed Web of Science ®Google Scholar
• Plas D. R., Thompson C. B. AKT-dependent transformation: there is more to growth than just surviving. Oncogene 2005; 24: 7435–7442
   PubMed Web of Science ®Google Scholar
• Datta S. R., Brunet A., Greenberg M. E. Cellular survival: a play in three AKTs. Genes Dev. 1999; 13: 2905–2927
   PubMed Web of Science ®Google Scholar
• Vivanco I., Sawyers C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002; 2: 489–501
   PubMed Web of Science ®Google Scholar
• Tomita M., Matsuda T., Kawakami H., Uchihara J. N., Okudaira T., Masuda M., Ohshiro K., Mori N. 1. Curcumin targets Akt cell survival signaling pathway in HTLV-I-infected T-cell lines. Cancer Sci. 2006; 97(4)322–327
   PubMed Web of Science ®Google Scholar
• Sun S. C., Yamaoka S. Activation of NF-kappaB by HTLV-I and implications for cell transformation. 1. Oncogene. 2005; 24(39)5952–5964
   PubMed Web of Science ®Google Scholar
• Sun S. C., Xiao G. Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metastasis Rev. 2003; 22(4)405–422
   PubMed Web of Science ®Google Scholar
• Satou Y., Nosaka K., Koya Y., Yasunaga J. I., Toyokuni S., Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004; 18(8)1357–1363
   PubMed Web of Science ®Google Scholar
• Mori N., Yamada Y., Ikeda S., Yamasaki Y., Tsukasaki K., Tanaka Y., Tomonaga M., Yamamoto N., Fujii M. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002; 100(5)1828–1834
   PubMed Web of Science ®Google Scholar
• Sanda T., Asamitsu K., Ogura H., Iida S., Utsunomiya A., Ueda R., Okamoto T. Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor. Leukemia 2006; 20(4)590–598
   PubMed Web of Science ®Google Scholar
• Cheng J. Q., Lindsley C. W., Cheng G. Z., Yang H., Nicosia S. V. The AKT/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005; 24: 7482–7492
   PubMed Web of Science ®Google Scholar
• Chollet P., Abrial C., Tacca O., Mouret-Reynier M. A., Leheurteur M., Durando X., Cure H. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin. Breast. Cancer 2006; 7(4)336–338
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., Goldman C. K., Bongiovanni K. F., Sharrow S. O., Davey M. P., Cease K. B., Greenberg S. J., Longo D. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72: 1805
   PubMed Web of Science ®Google Scholar
• Koon H. B., Severy P., Hagg D. S., Butler K., Hill T., Jones A. G., Waldmann T. A., Junghans R. P. Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk. Res. 2006; 30(2)190–203
   PubMed Web of Science ®Google Scholar
• Zhang Z., Zhang M., Goldman C. K., Ravetch J. V., Waldmann T. A. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003; 63(19)6453–6457
   PubMed Web of Science ®Google Scholar
• Mone A., Puhalla S., Whitman S., Baiocchi R. A., Cruz J., Vukosavljevic T., Banks A., Eisenbeis C. F., Byrd J. C., Caligiuri M. A., Porcu P. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-alpha-refractory adult T-cell leukemia. Blood 2005; 106(10)3380–3382
   PubMed Web of Science ®Google Scholar